Navigation Links
Nventa updates progress of cervical dysplasia trial with new HspE7
Date:10/18/2007

our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization, including Old Stressgen's 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC Publications Ltd.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. Wisconsin cities make progress on wireless Internet coverage
6. Doyle laments lack of progress on stem cell bill
7. U.S. health system could undermine EHR progress
8. Stem-cell controversies slow progress
9. VC trends, company progress discussed at Mason Wells portfolio meeting
10. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
11. Furious pace of Midwest biotech events marks progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... V. McCullar, Ph.D., Vice President of Drug,Discovery Operations, ... Investor Summit on Monday, September 15, 2008 at ...
... Data to be Presented at the 7th International ... Symposium on Uveitis ... a leading,developer of antibody fragment therapeutics, today announced that the,company ... lead product candidate, ESBA105, in ophthalmic indications. In,April 2008, ESBATech ...
... PRICING AVAILABLE ... ANYWHERE ... DEMOfall 08 conference here in San Diego, the launch of the,Familybuilder ... $59.95 DNA tests,the most affordable DNA testing available anywhere., At ...
Cached Biology Technology:SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 3
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... 24, 2013 For the first time, scientists at ... moderate-severe traumatic brain injury (TBI), atrophy (shrinkage) in the ... increased physical, social and cognitive stimulation. The ... in the chronic stages of traumatic brain injury," was ...
... (Sept. 24, 2013) Retinal (or fundus) photography is ... cameras can cost tens to hundreds of thousands of ... ophthalmic practices and to physicians in third-world countries. In ... Ear researchers describe the relatively simple technique of fundus ...
... researchers have identified and validated two rare gene mutations that ... that strikes after the age of 60. The two mutations ... enzyme involved in processing the amyloid precursor protein which ... the fifth AD gene overall. In their ...
Cached Biology News:Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 2Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 3Researchers use smart phone photography to diagnose eye disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 3
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
... c-Jun N-terminal kinase (JNK) is one of ... luciferase has been used as a sensitive ... Luciferase provides a 1000-fold increase in sensitivity ... (CAT) assay. Firefly luciferase catalyzes the oxidative ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: